Mochida Pharmaceutical Co Ltd (Mochida Pharma) develops new drugs, with focus on meeting medical needs such as treatments for intractable diseases and generic drugs. The company operates in critical areas including cardiology, obstetrics and gynecology, psychiatry, and gastroenterology. It also focuses on the development of biosimilars, nucleic acid drugs and regenerative medicine products. The company has one reportable segment, namely, pharmaceutical-related business. Mochida Pharma's product portfolio includes treatments for ulcerative colitis, chronic constipation, hyperlipidemia and arteriosclerosis obliterans, gout and hyperuricemia, pulmonary arterial hypertension, endometriosis, adenomyosis and dysmenorrhea, among others. The company also carries out drug discovery research, with a particular focus on nucleic acid drugs. In the field of regenerative medicine, Mochida Pharma is developing treatments using human dental pulp stem cells, highly purified mesenchymal stem cells, and the umbilical cord-derived cell drug HLC-001. The company is also working on various projects based on alginic acid and is engaged in the development, manufacturing, distribution and sales, academic research, and marketing of skin care products. The brands associated with the company include Lialda, Omvoh, Cortiment, Goofice, Movicol, Urece, Atelec, Lexapro and Tramcet. Mochida Pharma offers a comprehensive range of dermatological products tailored to specific skin needs. This includes products for sensitive skin, antimicrobial personal care, baby care, and nursing. Its product portfolio features the Collage series, which is meant for delicate skin, including Collage soap tailored to specific skin types, the moisturizing Collage D Medi Power series for dry skin, and the Collage Furfur Next shampoo and rinse with antimycotic agents for dandruff and itchy scalp. The company also offers Skina Babe for baby skin care, Skina Fukifuki and Skina Clen for skin cleansing, bed bath products, and Skina Dry Shampoo for bedridden individuals. The company distributes its products through specialty pharmacies and drugstores via mail orders. It collaborates with dermatologists to develop new and innovative products. The company manufactures injectables, solid oral pharmaceuticals and topical medicines through Mochida Pharmaceutical Plant Co Ltd (MPP) and develops skin care products through Mochida Healthcare Co Ltd (MHC). In FY2025, the company’s capital expenditure stood at JPY2,296 million, which grew 6% YoY.

Mochida Pharma is committed to advancing medical innovation through visionary creativity and cutting-edge research. Its R&D strategy focuses on both domestic and international collaborations, enhancing its drug discovery pipeline with new methods, including cells, nucleic acids, and genes. In drug discovery, it particularly focuses on nucleic acid drugs, investing in specialized talent and technologies to gain a competitive edge. This includes advancing research in regenerative medicine with projects centered on mesenchymal stem cells. It is developing treatments using human dental pulp stem cells (SHED) and highly purified mesenchymal stem cells (REC). It is also advancing the insomnia treatment ACT-541468, with Nexella Pharma Japan Co Ltd filing for manufacturing and marketing approval in October 2023. It has also filed for expanded indications of Treprost Inhalation Solution for pulmonary hypertension related to interstitial lung disease. Pediatric trials for Lialda (ulcerative colitis), Ulysse (gout and hyperuricemia) and MND-21 (hypertriglyceridemia) are progressing into Phase III trials. In the biomaterials sector, Mochida Pharma submitted a manufacturing and marketing approval application for the cartilage repair material dMD-001, and clinical trials in progress include dMD-002 for cavernous nerve injury and dMD-003 for adhesion prevention.